Individual generic drug information
Extracted information for Glimepiride only.
Type 2 diabetes mellitus ▶BY MOUTH ▶Adult: Initially 1 mg daily, adjusted according to response, then increased in steps of 1 mg every 1–2 weeks, increased to 4 mg daily, dose to be taken shortly before or with first main meal, the daily dose may be increased further, in exceptional circumstances; maximum 6 mg per day
Source pages 770, 771
Sulfonylureas should be avoided where possible in Acute porphyrias p. 1120 but glimepiride is thought to be safe.
Source page 771
Extracted information for Glimepiride only.
→Appendix 1: sulfonylureas
Source page 771
▶Rare or very rare Gastrointestinal discomfort. hypersensitivity vasculitis ▶Frequency not known Drug cross-reactivity
Source page 771
The use of sulfonylureas in pregnancy should generally be avoided because of the risk of neonatal hypoglycaemia.
Source page 771
Avoid—theoretical possibility of hypoglycaemia in the infant.
Source page 771
Manufacturer recommends regular hepatic and haematological monitoring but limited evidence of clinical value.
Source page 771
Extracted information for Glimepiride only.
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution Tablet ▶Glimepiride (Non-proprietary) Glimepiride 1 mg Glimepiride 1mg tablets | 30 tablet P £4.33 DT = £1.81 Glimepiride 2 mg Glimepiride 2mg tablets | 30 tablet P £7.13 DT = £1.94 Glimepiride 3 mg Glimepiride 3mg tablets | 30 tablet P £10.75 DT = £2.17 Glimepiride 4 mg Glimepiride 4mg tablets | 30 tablet P £14.24 DT = £3.07 ▶Amaryl (Zentiva) Glimepiride 3 mg Amaryl 3mg tablets | 30 tablet P £10.75 DT = £2.17 eiiii F 747
Source page 771
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
Initially 1 mg daily, adjusted according to
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 770
